VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	21.94M 19.22M 17.76M 16.39M 30.85M 2.11B 31.47M 212M 83.01M 1.03B 82.42M 80.59M 3.56B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	21.94M 19.22M 17.76M 16.39M 30.85M 2.11B 31.47M 212M 83.01M 1.03B 82.42M 80.59M 3.56B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	89.88%	Yield 2026 *	-	Yield 2027 *	-

07-10	VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026	CI
07-10	VYNE Therapeutics Declares Estimated $0.38-Per-Share Special Cash Dividend Ahead of Yarrow Merger	MT
05-15	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-27	VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
12-17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call
12-17	Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction.	CI
12-17	Vyne Therapeutics and Yarrow Bioscience announce merger agreement	RE
11-06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
11-06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/08/25	VYNE Therapeutics Inc. Announces Resignation of Christine Borowski as Member of the Board and as A Member of the Nominating and Corporate Governance Committee	CI
14/08/25	VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
31/07/25	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT

31/07/25	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
18/11/24	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
12/05/23	Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	MT
14/03/23	HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	MT
10/08/22	HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating	MT

07-10	VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience	AQ
05-21	VYNE Therapeutics : Yarrow Bioscience Investor Presentation	PU
12-17	VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement	AQ
11-06	VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update	AQ
14/08/25	VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update	AQ

Manager	Title	Age	Since
David Domzalski CEO	Chief Executive Officer	60	29/02/2020
Tyler Zeronda DFI	Director of Finance/CFO	40	-
Iain Stuart CTO	Chief Tech/Sci/R&D Officer	53	29/02/2020

Foamix Pharmaceuticals Ltd. Share Price Nasdaq

Stocks

IL0011334385

Biotechnology & Medical Research

Valuation: Foamix Pharmaceuticals Ltd.

Latest news : Foamix Pharmaceuticals Ltd.

Last Transcript: Foamix Pharmaceuticals Ltd.

Analysts' recommendations: Foamix Pharmaceuticals Ltd.

Press Releases: Foamix Pharmaceuticals Ltd.

Managers and Directors: Foamix Pharmaceuticals Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
David Domzalski BRD	Director/Board Member	60	29/02/2020
Sharon Barbari BRD	Director/Board Member	72	29/02/2020
Steven Basta BRD	Director/Board Member	61	31/12/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FOAMIX PHARMACEUTICALS LTD.	-.--%	-16.94%	-	-	21.94M
WUXI APPTEC CO., LTD.	+6.05%	+3.69%	+65.28%	+89.94%	53.54B
ARGENX SE	+0.21%	-6.28%	+56.18%	+127.90%	54.18B
INSMED INCORPORATED	+0.89%	-2.42%	+8.07%	+434.51%	23.66B
BIONTECH SE	+0.37%	-4.13%	-18.56%	-16.48%	22.78B
WUXI BIOLOGICS (CAYMAN) INC.	+2.36%	+1.06%	+43.34%	-6.14%	19.54B
GENMAB A/S	-2.29%	+1.78%	+34.98%	-28.10%	17.82B
PHARMAESSENTIA CORPORATION	-4.00%	-7.88%	+175.60%	+343.60%	16.01B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.15%	-4.83%	+46.53%	+627.30%	15.37B
EXELIXIS, INC.	-0.48%	-2.30%	+22.36%	+187.62%	14.09B
Average	+0.20%	-1.47%	+48.20%	+195.57%	26.33B
Weighted average by Cap.	+1.19%	-0.46%	+49.03%	+163.79%

	2026 *	2027 *
Net sales	-	-
Net income	-50M -43.79M -40.47M -37.34M -70.3M -4.81B -71.71M -483M -189M -2.35B -188M -184M -8.11B	-75M -65.68M -60.71M -56.02M -105M -7.21B -108M -724M -284M -3.53B -282M -275M -12.17B
Net Debt	-	-